» Articles » PMID: 28993551

Usefulness of Two-Compartment Model-Assisted and Static Overall Inhibitory-Activity Method for Prediction of Drug-Drug Interaction

Overview
Journal Biol Pharm Bull
Specialty Biochemistry
Date 2017 Oct 11
PMID 28993551
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Our study of drug-drug interaction (DDI) started with the clarification of unusually large DDI observed between ramelteon (RAM) and fluvoxamine (FLV). The main cause of this DDI was shown to be the extremely small hepatic availability of RAM (vF). Traditional DDI prediction assuming the well-stirred hepatic extraction kinetic ignores the relative increase of vF by DDI, while we could solve this problem by use of the tube model. Ultimately, we completed a simple and useful method for prediction of DDI. Currently, DDI prediction becomes more complex and difficult when examining issues such as dynamic changes in perpetrator level, inhibitory metabolites, etc. The regulatory agents recommend DDI prediction by use of some sophisticated methods. However, they seem problematic in requiring plural in vitro data that reduce the flexibility and accuracy of the simulation. In contrast, our method is based on the static and two-compartment models. The two-compartment model has advantages in that it uses common pharmacokinetics (PK) parameters determined from the actual clinical data, guaranteeing the simulation of the reference standard in DDI. Our studies confirmed that dynamic changes in perpetrator level do not make a difference between static and dynamic methods. DDIs perpetrated by FLV and itraconazole were successfully predicted by use of the present method where two DDI predictors [perpetrator-specific inhibitory activities toward CYP isoforms (pAs) and victim-specific fractional CYP-isoform contributions to the clearance (vfs)] are determined successively as shown in the graphical abstract. Accordingly, this approach will accelerate DDI prediction over the traditional methods.

Citing Articles

Treatment of Depression-Related Circadian Rhythm Sleep-Wake Disorder (CRSWD) With Melatonin Receptor Agonist Ramelteon: A Case Report.

Matsumoto S, Ohama R, Hoei T, Tojo R, Nakamura T Cureus. 2024; 16(8):e68311.

PMID: 39350880 PMC: 11441626. DOI: 10.7759/cureus.68311.


Developing mathematical models to compare and analyse the pharmacokinetics of morphine and fentanyl.

Shenoy P, Rao M, Chokkadi S, Bhatnagar S, Salins N Indian J Anaesth. 2024; 68(1):111-117.

PMID: 38406346 PMC: 10893797. DOI: 10.4103/ija.ija_1036_23.


Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug-Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil.

Iga K, Kiriyama A Clin Pharmacokinet. 2023; 63(1):43-56.

PMID: 37921907 DOI: 10.1007/s40262-023-01322-7.


A multi-centre, double-blind, randomized, placebo-controlled trial to evaluate the effectiveness and safety of ramelteon for the prevention of postoperative delirium in elderly cancer patients: a study protocol for JORTC-PON2/J-SUPPORT2103/NCCH2103.

Sadahiro R, Hatta K, Yamaguchi T, Masanori E, Matsuda Y, Ogawa A Jpn J Clin Oncol. 2023; 53(9):851-857.

PMID: 37340766 PMC: 10473272. DOI: 10.1093/jjco/hyad061.


Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.

Yadav J, Paragas E, Korzekwa K, Nagar S Pharmacol Ther. 2019; 206:107449.

PMID: 31836452 PMC: 6995442. DOI: 10.1016/j.pharmthera.2019.107449.